Table 3. Characteristics of the study population, by 1p/19q co-deletion status.
| 1p/19q co-deleted N = 901 |
Non co-deleted N = 1003 |
Incomplete N = 196 |
Unknown N = 11521 |
All N = 13621 |
p-value | ||
|---|---|---|---|---|---|---|---|
| Age | Median(years) | 37 (18–83) | 42 (18–80) | 38 (18–79) | 41 (18–90) | 41 (18–90) | < .01 |
| Gender | Male | 511 (56.7%) | 562 (56.0%) | 110 (56.1%) | 6447(56.0%) | 7630(56.0%) | 0.98 |
| Female | 390 (43.3%) | 441 (44.0%) | 86 (43.9%) | 5074(44.0%) | 5991(44.0%) | ||
| Race | White | 798 (88.6%) | 902 (89.9%) | 172 (87.8%) | 10179(88.4%) | 12051(88.5%) | 0.02 |
| Black | 51 (5.7%) | 46 (4.6%) | 11 (5.6%) | 729 (6.3%) | 837 (6.1%) | ||
| Other | 43 (4.8%) | 50 (5.0%) | 9 (4.6%) | 431 (3.7%) | 533 (3.9%) | ||
| Unknown | 9 (1.0%) | 5 (0.5%) | 4 (2.0%) | 182 (1.6%) | 200 (1.5%) | ||
| Hispanic | Unknown | 23 (2.6%) | 29 (2.9%) | 7 (3.6%) | 809 (7.0%) | 868 (6.4%) | <0.01 |
| No | 810 (89.9%) | 907 (90.4%) | 174 (88.8%) | 9840 (85.4%) | 11731(86.1%) | ||
| Yes | 68 (7.5%) | 67 (6.7%) | 15 (7.7%) | 872 (7.6%) | 1022 (7.5%) | ||
| Tumor location | NOS | 118 (13.1%) | 116 (11.6%) | 35 (17.9%) | 1989 (17.3%) | 2258 (16.6%) | < .01 |
| Cerebrum | 764 (84.8%) | 884 (88.1%) | 159 (81.1%) | 9079 (78.8%) | 10886(79.9%) | ||
| Midline | 19 (2.1%) | 3 (0.3%) | 2 (1.0%) | 453 (3.9%) | 477 (3.5%) | ||
| Charlson- | 0 | 774 (85.9%) | 850 (84.7%) | 168 (85.7%) | 9867 (85.6%) | 11659(85.6%) | 0.76 |
| Deyo | 1 | 93 (10.3%) | 101 (10.1%) | 20 (10.2%) | 1190 (10.3%) | 1404 (10.3%) | |
| Score | 2 | 23 (2.6%) | 38 (3.8%) | 7 (3.6%) | 358 (3.1%) | 426 (3.1%) | |
| ≥3 | 11 (1.2%) | 14 (1.4%) | 1 (0.5%) | 106 (0.9%) | 132 (1.0%) | ||
| Facility | Unknown | 518 (57.5%) | 443 (44.2%) | 105 (53.6%) | 5246 (45.5%) | 6312 (46.3%) | < .01 |
| Type | Community | 135 (15.0%) | 225 (22.4%) | 38 (19.4%) | 2960 (25.7%) | 3358 (24.7%) | |
| Academic | 248 (27.5%) | 335 (33.4%) | 53 (27.0%) | 3315 (28.8%) | 3951 (29.0%) | ||
| Living area | Unknown | 26 (2.9%) | 34 (3.4%) | 4 (2.0%) | 439 (3.8%) | 503 (3.7%) | 0.96 |
| Metro | 730 (81.0%) | 797 (79.5%) | 152 (77.6%) | 9262 (80.4%) | 10941(80.3%) | ||
| Rural | 145 (16.1%) | 172 (17.1%) | 40 (20.4%) | 1820 (15.8%) | 2177 (16.0%) | ||
| Treatment | Unknown | 37 (4.1%) | 48 (4.8%) | 7 (3.6%) | 665 (5.8%) | 757 (5.6%) | < .01 |
| None | 40 (4.4%) | 40 (4.0%) | 7 (3.6%) | 1022 (8.9%) | 1109 (8.1%) | ||
| RT+CT+S | 138 (15.3%) | 102 (10.2%) | 31 (15.8%) | 1184 (10.3%) | 1455 (10.7%) | ||
| RT+CT | 41 (4.6%) | 36 (3.6%) | 12 (6.1%) | 825 (7.2%) | 914 (6.7%) | ||
| RT+S | 115 (12.8%) | 79 (7.9%) | 27 (13.8%) | 1348 (11.7%) | 1569 (11.5%) | ||
| CT+S | 56 (6.2%) | 181 (18.0%) | 14 (7.1%) | 645 (5.6%) | 896 (6.6%) | ||
| S only | 417 (46.3%) | 444 (44.3%) | 92 (46.9%) | 4705 (40.8%) | 5658 (41.5%) | ||
| RT only | 39 (4.3%) | 21 (2.1%) | 2 (1.0%) | 772 (6.7%) | 834 (6.1%) | ||
| CT only | 18 (2.0%) | 52 (5.2%) | 4 (2.0%) | 355 (3.1%) | 429 (3.1%) | ||
| Insurance status | Not Insured | 57 (6.3%) | 68 (6.8%) | 14 (7.1%) | 808 (7.0%) | 947 (7.0%) | < .01 |
| Private | 639 (70.9%) | 741 (73.9%) | 136 (69.4%) | 7629 (66.2%) | 9145 (67.1%) | ||
| Medicaid | 110 (12.2%) | 98 (9.8%) | 25 (12.8%) | 1236 (10.7%) | 1469 (10.8%) | ||
| Medicare | 69 (7.7%) | 72 (7.2%) | 18 (9.2%) | 1374 (11.9%) | 1533 (11.3%) | ||
| Other Gov’t | 20 (2.2%) | 18 (1.8%) | 1 (0.5%) | 215 (1.9%) | 254 (1.9%) | ||
| Unknown | 6 (0.7%) | 6 (0.6%) | 2 (1.0%) | 259 (2.2%) | 273 (2.0%) |
NOS: Not otherwise specified; RT: Radiation therapy; CT: Chemotherapy; S: Surgery